Lissoni Paolo, Malugani Fabio, Brivio Fernando, Piazza Alessandra, Vintimilla Carmen, Giani Luisa, Tancini Gabriele
Division of Radiation Oncology, S. Gerardo Hospital, Monza (Milan), Italy.
Neuro Endocrinol Lett. 2003 Jun-Aug;24(3-4):259-62.
It is known since many years that the pineal gland plays an anticancer role, and melatonin (MLT), the most investigated pineal hormone, has been proven to exert antitumor activity. However, MLT would not be the only hormone responsible for the antitumor action of the pineal gland. In fact, recent advances in the pineal investigations have shown that pineal indoles other than MLT may also exert anticancer activity, namely the three main indoles, consisting of 5-methoxytriptamine (5-MTT), 5-methoxytryptophol (5-MTP) and 5-methoxy-indole acetic acid (5-MIA). Cancer progression has appeared to be associated with a concomitant decline in the pineal endocrine function. Therefore, the replacement of a complete pineal function in the advanced cancer patients would require the exogenous administration of the overall four pineal indoles. Several clinical studies have shown that MLT alone at pharmacological doses may induce a control of the neoplastic progression in about 30% of untreatable metastatic solid tumor patients. The present study was performed in an attempt to evaluate the therapeutic of a total pineal endocrine substitution therapy with its four indole hormones in cancer patients, for whom no other conventional therapy was available.
The study included 14 metastatic solid tumor patients, who had failed to respond to the conventional anticancer therapies. The pineal indoles were given orally according to a schedule elaborated in an attempt to reproduce their physiological circadian secretion during the daily photoperiod. MLT was given at 20 mg/day during the night, whereas the other indoles were given at 1 mg/day, by administering 5-MIA in the morning, 5-MTP at noon and 5-MTT in the afternoon.
A disease-control was achieved in 9/14 (64%) patients, consisting of partial response (PR) in one patient and stable disease (SD) in the other 8 patients. The median time of disease-control (PR + SD) was 6 months (range: 4-10).
This preliminary study shows that a total pineal endocrine replacement therapy by an exogenous administration of the overall four pineal indoles may induce a disease-control in about 60% of untreatable metastatic solid tumor patients. Then, these results would be clearly superior with respect to those described with MLT alone, by confirming in humans that MLT is not the only hormone responsible for the anticancer property of the pineal gland. Since Cartesius was the first author who suggested the fundamental role of the pineal in the connection between consciousness and biological life, this therapy could be defined as a Cartesian therapy.
多年来已知松果体发挥抗癌作用,褪黑素(MLT)作为研究最多的松果体激素,已被证明具有抗肿瘤活性。然而,MLT并非松果体抗肿瘤作用的唯一激素。事实上,松果体研究的最新进展表明,除MLT外的其他松果体吲哚也可能具有抗癌活性,即三种主要吲哚,包括5-甲氧基色胺(5-MTT)、5-甲氧基色醇(5-MTP)和5-甲氧基吲哚乙酸(5-MIA)。癌症进展似乎与松果体内分泌功能的同时下降有关。因此,对于晚期癌症患者,要恢复完整的松果体功能需要外源性给予全部四种松果体吲哚。多项临床研究表明,药理学剂量的单独MLT可使约30%无法治疗的转移性实体瘤患者的肿瘤进展得到控制。本研究旨在评估用四种吲哚激素进行松果体全内分泌替代疗法对无其他常规治疗方案的癌症患者的治疗效果。
该研究纳入了14例对常规抗癌治疗无反应的转移性实体瘤患者。根据精心制定的给药方案口服松果体吲哚,以试图重现其在每日光照周期中的生理昼夜分泌。夜间给予MLT 20mg/天,而其他吲哚每天给予1mg,早上给予5-MIA,中午给予5-MTP,下午给予5-MTT。
9/14(64%)例患者病情得到控制,其中1例部分缓解(PR),8例病情稳定(SD)。病情控制(PR + SD)的中位时间为6个月(范围:4 - 10个月)。
这项初步研究表明,外源性给予全部四种松果体吲哚进行松果体全内分泌替代疗法可使约60%无法治疗的转移性实体瘤患者病情得到控制。那么,这些结果明显优于单独使用MLT时的结果,从而在人体中证实MLT并非松果体抗癌特性的唯一激素。由于笛卡尔是首位提出松果体在意识与生物生命联系中起基本作用的作者,这种疗法可被定义为笛卡尔疗法。